礼新医药临床运营副总裁。曾在精鼎、方恩等CRO公司任职并负责方恩临床运营工作，此后在罗氏以及珐博进、华领、康宁杰瑞等Biotech企业担任临床运营部门负责人，负责多项国际国内研究，并助力多项1.1类新药成功获批。

Paul Kong, leads Clinical Operation team within LaNova since Apr, 2021. He has more than 10 years experiences in CRO, such as Parexel and FMD, and then taking the leading role from various biotechs and big pharm, Roche, FibroGen, Hua Medicine and Alphamab in clinical operation team; and he has major contributions for lots of first in class production registration.

Dr. Li ZENG joined Jing Medicine as Chief Executive Officer in November 2021, bringing with him a wealth of R&D and business operation experience in the pharmaceutical industry with a career spanning over 18 years. He has held drug R&D, portfolio and project management positions of increasing responsibilities in multinational companies such as Novartis and Eli Lilly as well as in traditional local pharma and biotech firms such as Luoxin Pharmaceutical, 4B Technologies and Harbour Biomed.

Dr. Zeng received his bachelor’s degree in chemistry from Peking University and Ph.D. in Organic Chemistry from Stanford University. He conducted his postdoctoral research training in Chemical Biology at University of California, Berkeley.

曾雳博士于2021年11月加入和径医药担任首席执行官，拥有超过19年的新药研发和管理经验。曾博士先后在跨国药企诺华公司和礼来公司负责新药研发和项目管理，以及在罗欣药业、福贝生物和和铂医药等民营企业和生物技术公司负责战略规划和运营、新药产品线和项目管理。

曾博士分别在北京大学和斯坦福大学获得化学学士和有机化学博士学位，并在加州大学伯克利分校完成化学生物学的博士后训练。

Over 18 years of experience in clinical research and 9 years in digital CRO. Holds an MBA from The University of Hong Kong and is a pioneer in decentralized clinical trial (DCT) practices in China.​

Previously worked at world-renowned companies such as Roche, PPD, and Chiltern, leading multiple large-scale regional studies as the China lead, managing projects across nearly 150 research sites.​

Key Contributions: Co-author of *Real-World Research Guidelines 2018*; Co-author of Medical Code in the AI Era; Co-author of Blue Book on Remote & Intelligent Clinical Trials; Committee member of DIA (Drug Information Association), involved in oncology researcher training programs.​

18余年临床研究领域经验，9余年医疗数字化创业经历。香港大学工商管理学硕士，DCT中国临床研究实践的先行者。​

曾就职于罗氏、PPD、Chiltern等世界知名企业，参与多项大型regional study 任中国区负责人，负责近150家研究中心的项目管理工作。《真实世界研究指南2018 》执笔专家之一, 《AI时代医学密码》执笔专家之一，《远程智能临床试验蓝皮书》执笔专家之一，同时担任DIA组委会成员参与肿瘤研究者培训工作。

Over 22 years of multinational corporation (MNC) experience in full lifecycle product development, real-world evidence, new product launch, pharmacovigilance, and GxP QMS compliance & auditing across oncology and specialty therapeutic areas.

Prior to DCTA and Trial Data, held positions at Roche China Medical Affairs and Eli Lilly Global R&D.

Master of Medicine in Hematology from Shanghai Jiao Tong University School of Medicine; practiced hematology at Hôtel-Dieu Hospital in Paris, France and Ruijin Hospital in Shanghai, China.

拥有超过22年跨国企业工作经验，负责全生命周期产品研发以及真实世界证据、新产品上市、药物安全警戒以及GxP质量管理体系合规与审计等多个方面，涉及多个肿瘤和特药治疗领域。

加入创达之前，先后在罗氏中国医学事务部、礼来全球研发担任多个职位。

毕业于上海交通大学医学院，获得血液学医学硕士学位，曾在法国巴黎Hotel Dieu Hospital和上海瑞金医院血液科就职参加临床工作。

Limin Guan has 17 years of experience in the pharmaceutical industry, beginning with technical roles in drug substance process development within a pilot plant setting. Over the past 10 years, he has honed his expertise in clinical supply chain management, starting his journey at Novartis. His professional background includes integrating global supply chain experience across the US, EU, APAC, and beyond, through roles at Novartis, Zailab, Beigene, and Takeda, with a particular focus on the Asia-Pacific region. Currently, Limin provides leadership and strategic direction for Clinical Supply Chain activities in China and the APAC region. His responsibilities include overseeing outsourced operations, serving as the Global Clinical Supply Chain representative to local functions, and advancing capabilities in project planning and execution.

管利民在制药行业拥有17年的经验，最初从事药物原料工艺开发的技术工作，主要集中在中试车间领域。在过去的10年里，他在临床供应链管理方面积累了丰富的经验，并从诺华开始了这一领域的职业旅程。他的职业背景包括在诺华、再鼎、百济和武田公司等担任职务，整合了在美国、欧洲、亚太地区及其他地区的全球供应链经验，尤其专注于亚太区域。目前，他负责领导和制定中国及亚太地区临床供应链活动的战略方向。他的职责涵盖监督外包业务，作为武田全球临床供应链与当地职能部门之间的代表，并推动项目规划与执行能力的提升。

Dr. Siwei Li, Director of DMPK at Degron Therapeutics. Dr. Li earned his B.S. in Biotechnology from Nanjing University in 2008 and received his Ph.D. in Chemistry from the University of Cincinnati (USA) in 2014. Then he served as postdoctoral research fellow at the University of Michigan College of Pharmacy and also obtained a professional certificate in Data Science from Stanford University. With over 10 years of experience in drug discovery and development, Dr. Li has held key positions including Director of AI Pharmacology at an AI Drug Discovery biotech company, Senior Principal Investigator at BeiGene, and Research Scientist at a Silicon Valley precision medicine company. He is also recognized as an Elsevier Outstanding Reviewer for Food Chemistry journal. His research focuses on small molecule non-clinical pharmacokinetics, Model-Informed Drug Discovery (MIDD): PKPD and AI model development and application in drug discovery and development, Bioanalytical technology development and application, AI-driven proteomics and metabolomics research. Dr. Li has contributed to 10+ drug discovery programs and led/participated in non-clinical PK studies supporting multiple China-US IND filings. To date, he has published over 20 papers in internationally renowned journals and filed 1 patent application.

李四维博士，达歌生物药代动力学总监。2008年毕业于南京大学生物技术专业本科，2014年获美国辛辛那提大学化学博士学位。随后在美国密西根大学药学院从事博士后研究，并获斯坦福大学数据科学职业认证。李博士拥有10余年的药物研发经验，曾先后担任AI制药公司AI药理总监、百济神州高级主任研究员及美国硅谷精准医学公司研究科学家。同时，他还是爱思唯尔《Food Chemistry》期刊的杰出审稿人。李博士的研究方向聚焦于小分子非临床药代动力学研究；模型引导的药物研发(MIDD): PKPD模型和AI模型在药物研发中开发和应用；生物分析技术开发与应用。他还在AI赋能蛋白质组学及代谢组学研究方向拥有多年实践经验。曾参与10余个新药研发项目，并主导参与多个中美IND申报相关的非临床药代动力学研究工作。迄今在国际知名期刊发表论文20余篇及申请专利1项。

Fiona Xing is currently serving as the Head of Clinical Supply Chain at Brii Bioservices (Beijing) Co., Ltd. She entered the pharmaceutical industry in 2005 and worked at Servier, Allergan, Bayer R&D Center and Merck Serono R&D Center, mainly engaged in local and global clinical trial supply chain coordination and management. ​

Fiona Xing holds a master‘s degree in microbiology from Shandong University and an MBA degree from Sofia University in the United States. In addition, Fiona Xing has obtained professional Project Management (PMP) and Program Management (PgMP) certification from the American Project Management Institute.

邢新苗目前任职于腾盛博药医药技术（北京）有限公司，担任临床供应链负责人。她从2005年进入医药行业，先后任职于施维雅，艾尔建，拜耳研发中心，默克雪兰诺研发中心，主要从事中国以及全球临床试验供应链协调和管理工作。​

邢新苗拥有山东大学微生物学专业硕士学位，并获得美国索菲亚大学MBA学位。 此外，邢新苗持有美国项目管理协会的专业项目管理和项目集管理认证。

Ellen Guan has over 15 years of extensive experience in regulatory affairs, covering the entire life cycle of new biologics and chemical drugs. She joined 3DMedicines in 2016 and is currently the Head of Regulatory Affairs department. She led her team to complete the registration work for the global first subcutaneous PD-L1 antibody injection, Envefolimab, in China, as well as seveal IND and pivotal clinical trials in the United States and Japan. She is familiar with the regulations for marketing applications in the Asia-Pacific region and maintains the registration work for post-marketing amendment in China. Before joining 3DMedicines, she worked at BeiGene and was responsible for the global IND filings and approvals of several of BeiGene's self-developed products.

关怡在药品注册领域拥有超过15年的丰富经验，涵盖生物制品及化学药品新药的全生命周期。2016年加入思路迪医药，目前是该公司药政事务负责人，主持并带领团队完成全球首个皮下注射PD-L1恩沃利单抗注射液的中国上市及美国和日本IND及关键临床的注册工作，熟悉亚太地区的上市申请法规，维护产品在中国上市后变更的注册工作。2016年之前曾就职百济神州，负责数个百济自主研发品种的全球IND申报及批准。

James Liu , Licensed Attorney，holding LL.M.s both from the University of Manchester and one of the top China’s university, as well as a Ph.D. in Management, with twenty years of dedicated experience in the biopharmaceutical and high-tech investment sectors. As a founding practitioner (Founder), I lead the formulation of corporate-wide strategy and development roadmaps, concentrating on core drivers for business growth: effectively integrating critical resources (particularly governmental relations and public policy resources), establishing deep public-private collaborative ecosystems, accurately discerning industry policy trends and driving their translation into execution to ensure corporate compliance and sustained competitive advancement. Leveraging comprehensive expertise spanning R&D, manufacturing, operations management, to investment and financing, I am committed to accelerating the industrialization of innovative achievements and steering organizations toward high-quality, sustainable growth.

刘 James，执业律师，拥有国内外著名高校生物化学本科、双法学硕士及管理学博士学位，于生物医药与高科技投资领域持续深耕二十年。 作为创业实践者（Founder），主导制定企业整体战略与发展路径，聚焦驱动业务增长的核心要素：高效整合关键资源（尤其是政府关系与公共政策资源）、构建深度政企协同生态、精准研判产业政策趋势并推动落地转化，确保企业合规经营与竞争力持续提升。 凭借覆盖研发、生产、管理至投融资的综合经验，致力于促进创新成果产业化，引领企业实现高质量的可持续增长。

"Tessa Lai—Director, CSC Logistics APAC Warehouse & Distribution Operations Tessa has 15+ years’ experience in clinical supply including supply planning, manufacture, packaging, importation, logistic management and comparator sourcing. As the clinical supply Chain Logistic Asian Director, she manages all APAC clinical supply warehouses and logistic activities, oversees the clinical supply in China (mainland, Hong Kong, Taiwan), Japan, Korea, Australia, India and other Asian countries. Her team also manages APAC local comparator sourcing and related packaging and labelling."

"赖会明——CSC物流亚太区仓储与配送运营总监 赖会明在临床供应领域拥有超过15年的丰富经验，涵盖供应计划、生产、包装、进口、物流管理及对照药采购等全流程。 作为临床供应链物流亚洲区总监，她全面负责亚太地区所有临床供应仓库及物流运营管理，监管中国（大陆、香港、台湾）、日本、韩国、澳大利亚、印度及其他亚洲国家/地区的临床物资供应。其团队还主导亚太本土对照药采购及相关的包装标签业务。"

With 16 years of deep expertise in the clinical operations industry, Vincent Zang has previously worked at ICON, Johnson & Johnson, and Simcere Pharmaceutical. In 2019, he joined Innovent Biologics, where he has been involved in the full lifecycle clinical development of multiple drugs (including small molecule chemicals, monoclonal antibodies, bispecific antibodies, peptides, etc.), with several products successfully approved for market launch. He has accumulated extensive experience in novel drug clinical development.

臧文升在临床运营行业已深耕16年。曾就职于于ICON、强生、先声药业，2019年加入信达生物。承担过多项药物（小分子化药、单抗、双抗、多肽等）的临床开发的全阶段的工作，并已有多个产品成功获批上市。在新药临床开发方面积累了丰富的经验。

Megan Qin has over 15 years of experience in the healthcare industry and is a PMI-certified Project Management Professional specializing in clinical research project management, clinical pathway planning, clinical operations, and innovative intelligent solutions. She has held positions at world-renowned healthcare companies including Roche Medical, Bard Medical (BD), BI (Boehringer Ingelheim), and Stryker Neurovascular, where she served as the Head of Clinical Affairs for China, accumulating extensive knowledge and hands-on experience in GCP (Good Clinical Practice) for drugs and medical devices. She is particularly passionate about innovative medical devices, optimizing clinical data applications, and implementing project management risk controls.
Currently, she also holds roles as Committee Member of Medical Device Clinical Trial Quality Management Committee-China Association of Rehabilitation of Disabled Persons and Working Group Member of DIA Real-World Evidence Research Group.

秦飞拥有超过15年的医疗行业经验，PMI认证项目管理专家，专注于临床研究领域项目管理，临床路径规划，临床运营及创新智能化解决方案。她曾就职于罗氏制药、巴德医疗（碧迪医疗）、BI(勃林格殷格翰)以及史赛克医疗等世界知名医疗企业，曾担任中国区临床事务负责人，积累了丰富的药物及医疗器械GCP的知识和实践经验，在创新医疗器械、优化临床数据的应用，实施项目管理风险管控等方面尤其热衷。现兼任中国残疾人康复协会-医疗器械临床试验质量管理专业委员会委员，DIA真实世界研究工作组成员。

邓晓宇先生拥有17年全球多区域医药研究开发经验，曾在多个国际领先的临床研究组织担任重要职务，包括 Labcorp、Syneos、Chiltern 和 Covance，并帮助多个亚太区企业在欧洲和美国开展医药产品临床研发工作。在新冠疫情期间，他成功领导了 Covance 亚太区的首个新冠临床研究。作为希毅医学的创始人，他带领公司帮助 80 多项生物医药项目在海外顺利落地。
邓晓宇先生毕业于哈佛大学流行病与临床试验专业，同时他也是美国项目管理协会认证项目管理专家，注册药剂师。

Xiaoyu Deng, has over 17 years of experience in global clinical research and development. Mr. Deng is a recognized expert in planning and executing clinical trials across diverse global regions. He has held key positions at leading international CROs, including Labcorp, Syneos, Chiltern, and Covance. During the COVID-19 pandemic, Mr. Deng successfully led the first COVID-19 study in the APAC region for Covance, demonstrating his ability to lead high-stakes research under tight timelines.
As the founder of MDCE, Mr. Deng has guided the company to substantial success, generating over 20 billion RMB in profits for its clients and helping more than 80 Chinese medical devices and drug products successfully land overseas.
Mr. Deng holds a Master’s degree in Public Health (Epidemiology) from Harvard University’s T.H. Chan School of Public Health. He is also a certified Project Management Professional (PMP), and a licensed pharmacist.

Head of International Cooperation, Linscope Institute for Life and Health Innovation. Over 20 years of leadership experience in multinational pharmaceutical and medical-device companies, spanning medical affairs, marketing, sales management, and strategy. Eight years as a principal consultant to global biopharma enterprises. Former oncologist at Zhongshan Hospital affiliated to Fudan University.

现任领思生命健康创新研究院 国际合作部主任。20余年跨国医药和器械公司管理，包括医学、市场、销售管理、战略等。8年跨国生物医药行业首席咨询顾问。原复旦大学附属中山医院肿瘤专业医师。

Fiona Barry is Editor-in-Chief & Director of Outsourcing at GlobalData, where she leads the PharmSource division in gathering news, data and analysis about contract manufacturing. She has covered the pharma industry for more than a decade, as a journalist and analyst.

Shelly毕业于沈阳化工大学高分子化学专业，拥有超过15年在跨国制药企业（MNC）从事商业及临床供应链管理的经验。曾任职于科文斯、赛诺菲和安进等跨国药企，期间支持亚太研发中心的建立以及多个产品的中国上市、进口与本地化转产项目，并参与肿瘤、代谢、自身免疫等治疗领域的中美及亚太区域I~III期临床试验供应。Shelly于2023年加入礼来中国，现任临床及QC供应链负责人，持续推动中国同步研发策略，强化本地与全球供应流程衔接、注册用药保障及团队能力建设，并积极参与临床供应相关的外部生态系统建设

Shelly graduated from Shenyang University of Chemical Technology with a major in Polymer Chemistry. She has over 15 years of experiences in commercial and clinical supply chain management in multinational pharmaceutical companies (MNCs) including Covance, Sanofi and Amgen, during which she supported the establishment of Asia-Pacific R&D centers, as well as multiple projects involving the launch, import and localization switching of products in China. At the meanwhile, she has also participated in the supply for Phase I-III clinical trials in China, the United States and the Asia-Pacific region in therapeutic areas such as oncology, metabolism and autoimmune diseases.

王晓梅，北京大学医学部流行病与卫生统计学硕士。拥有10年以上国际项目管理经验和10年+Biotech公司创新药研发工作经验。熟悉药物研发临床前研究、IND申报和临床开发等工作，包括临床开发计划、临床试验方案制定；数据管理、统计分析、药物安全管理等领域，领导完成了多个在中国、美国和澳大利亚开展的I/II期临床试验，参与多个化合物中、美、澳新药临床试验IND申请和pre-IND沟通交流工作以及临床前研究工作。现负责凯复医药全球临床运营和法规注册工作。 

Mrs. Wang received her Master of Epidemiology and Health Statistics from Peking University Health Science Center. With over 10 years of Global project management experience in China CDC and Damien Foundation Belgium and more than 10 years of innovative drug research and development experience in Biotech companies. She has been involved in preclinical research and development, IND application, and clinical operations, including data management, statistical analysis, and drug safety management. Mrs. Wang has led the completion of multiple Phase I and Phase II clinical trials in China, Australia, and the United States, and participated in the IND applications and pre- IND preparations, as well as preclinical researches for a variety of new drugs in China, Australia, and the United States. Currently she is in charge of the global clinical operations and regulatory affairs of Keythera Bio-Pharmaceuticals. 

Ms Cherry Zhang joined the Australia New South Wales government in Shanghai in 2012. She is dedicated to promoting bilateral trade and investment, maintaining government relations, and facilitating cooperation across multiple fields. She provides services to businesses interested in trading and investing in Sydney and New South Wales and assists New South Wales businesses in exploring opportunities in China, introducing new products and services to the Chinese and Australian markets.

张婧怡女士于2012年加入澳大利亚新南威尔士州政府上海办公室，致力于推进双边贸易投资，维系政府关系及多领域的合作。张女士为有意在悉尼和新南威尔士州进行贸易和投资的企业提供服务，并为希望在中国寻求商机的新南威尔士州企业提供帮助，将新的产品和服务引入中国市场和澳洲市场。

Mr. Chester Xiao is the Director of Life Sciences for IDA Ireland in China. IDA Ireland is the investment promotion agency of the Irish Government. Over the past 50 years, IDA Ireland has successfully established Ireland as one of the world's leading investment destinations and transformed Ireland into a 'knowledge economy'. Now IDA Ireland supports more than 1,800 client companies and operates internationally from its base in Ireland.

肖嘉先生目前担任爱尔兰投资发展局（IDA）的中国区生命科学行业总监。爱尔兰投资发展局是爱尔兰政府的投资促进机构。在过去的五十年里爱尔兰投资发展局成功将爱尔兰打造为全球领先的投资目的地之一，成功实现爱尔兰向“知识经济”的转型。爱尔兰投资发展局支持1800多家客户企业，以爱尔兰为基地开展面向国际市场的业务。

Vikki Wang has been with the China office of Maryland Department of Commerce since 2009 and has accumulated many years of experiences in international trade and investment consulting, supporting for Maryland companies’ business interests in China as well as Chinese companies going to Maryland. Past clients span across industries such as medical health, biotech, manufacturing, logistics, agriculture and others.

王艳波女士自2009年加入马里兰州中国办公室至今，拥有多年国际贸易和投资咨询经验，为马里兰州企业在华业务及中国企业赴美投资提供支持，曾服务的客户涉及医疗健康、生物技术、制造业、物流、农业等多个行业。

"With decades of experience in the healthcare industry and clinical research, Ted specializes in clinical operations, project management, data management, and innovative solutions. He also possesses a diverse management background across healthcare, life sciences, telecommunications, and aerospace. Currently he serves as regulatory and clinical consultant to three USA based medical device startup companies in Neurovascular, Cardiovascular and Orthopedic therapies and he was the leader of Stryker Neurovascular's global clinical operations team, overseeing pre and post-market clinical studies around the world (including China). He possesses a deep understanding of global device regulations and has successfully driven the launch of numerous innovative products. "

Dr. Claudia Hesselmann, a chemist by training, with a PhD in molecular biology. Claudia has twenty years of expertise in the early phases of drug development. Her experience includes co-founding and holding management positions in various CROs. Her extensive background and social acumen, along with her first-hand knowledge of the industry, led Claudia to co-found ARENSIA Exploratory Medicine in Düsseldorf, Germany. Her primary aim is the contribution of innovative approaches to bring about substantial acceleration to the drug development process and enable more agile patient access to novel therapeutics.

Chris has dedicated his 16-year career to the services side of the Phase I clinical drug development industry, including both operational and business development roles. Having worked within all major biopharma markets including USA, Japan, China, EU and Australia has enabled him to become a trusted advisor to many customers and help them achieve their clinical drug development objectives. Chris’ deep knowledge of the global early phase drug development industry strengthens the tradition of success of Nucleus Network, our customers and partners in “Advancing Medicines, Improving Lives”.

Hedy Xiang is a dynamic commercial business development with 15+ years of experience in life science, pharmaceutical packaging and clinical trial supply solutions. Since joining Smurfit WestRock in August 2023 as Adherence and Clinical Solutions Manager for APAC, she has been instrumental in expanding the company’s global capabilities across the Asia-Pacific region. Her focus includes patient-centric adherence & clinical trial packaging, child-resistant/senior-friendly (CR/SF) solutions, and innovative digital platforms for clinical trials.

Her expertise spans strategic business development, cross-functional collaboration, and end-to-end supply chain optimization for pharmaceutical and biotech industries.

Hedy holds a master’s degree from Shanghai Jiao Tong University and combines technical knowledge with commercial acumen to deliver tailored solutions that enhance medication adherence and clinical trial efficiency across not just APAC but Global markets.

项婧是生命科学和医药包装领域的资深专家，拥有超过15年的行业经验。自2023年8月加入 Smurfit WestRock 担任亚太地区的合规与临床解决方案经理以来，她在扩展公司在亚太地区的全球能力方面发挥了重要作用。她的工作重点包括以患者为中心的依从性以及临床试验包装、儿童安全/老年友好（CR/SF）解决方案，以及用于临床试验的创新数字平台。

她的专业领域涵盖战略业务发展、跨职能合作，以及针对制药和生物科技行业的端到端供应链优化。

项婧拥有上海交通大学的硕士学位，将技术知识与商业敏锐度结合，提供量身定制的解决方案，从而提高亚太市场到全球化的药物依从性和临床试验效率。